Ascendis Pharma A/S (NASDAQ:ASND) Short Interest Update

Ascendis Pharma A/S (NASDAQ:ASND) saw a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 3,420,000 shares, a drop of 5.5% from the December 15th total of 3,620,000 shares. Based on an average trading volume of 426,500 shares, the days-to-cover ratio is currently 8.0 days.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ:ASND opened at $128.13 on Monday. The company has a 50 day moving average price of $133.13 and a two-hundred day moving average price of $133.47. The company has a market capitalization of $7.78 billion, a PE ratio of -15.86 and a beta of 0.65. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $161.00.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. TD Cowen decreased their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Wedbush restated an “outperform” rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. JPMorgan Chase & Co. decreased their price objective on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 23rd. UBS Group initiated coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a “buy” rating and a $196.00 target price for the company. Finally, Stifel Nicolaus raised their price target on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $192.07.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ASND. Wilmington Savings Fund Society FSB acquired a new position in shares of Ascendis Pharma A/S in the third quarter valued at approximately $30,000. Groupama Asset Managment bought a new stake in shares of Ascendis Pharma A/S during the 3rd quarter worth approximately $60,000. GAMMA Investing LLC boosted its holdings in shares of Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 214 shares during the last quarter. Signaturefd LLC grew its stake in shares of Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 80 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after buying an additional 143 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.